Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826497 | 1.00 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13826385 | 0.89 | GRM5 (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13739590 | 0.88 | ADORA1 (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13739293 | 0.88 | MAPT (0.46) | GRM5KDM4EMAPK1HSD17B10MEN1 | |
| SCHEMBL13826287 | 0.88 | MAPT (0.46) | GRM5KDM4EMAPK1HSD17B10MEN1 | |
| SCHEMBL13738847 | 0.86 | PDE10A (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13739431 | 0.86 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13738551 | 0.86 | PDE10A (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13739588 | 0.84 | PDE10A (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13737469 | 0.84 | GRM5 (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9079909-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | USHER III INITIATIVE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079909-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | USHER III INITIATIVE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079909-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | USHER III INITIATIVE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012148994-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, PDE6B | PIK3CD 4135/4885PIK3CA 3254/4885PIK3CB 3139/4885 |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | PIK3CD 4566/4885PIK3CA 4592/4885PIK3CB 4268/4885 |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | PIK3CD 4118/4885PIK3CA 3204/4885PIK3CB 3128/4885 |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | ALDH1A2, ALDH1A3, NR2E3 | PIK3CD 4118/4885PIK3CA 3204/4885PIK3CB 3128/4885 |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | PIK3CD 4118/4885PIK3CA 3204/4885PIK3CB 3128/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | PIK3CD 2472/4885PIK3CA 2276/4885PIK3CB 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.